Bioceres Crop Solutions Corp. reported its fiscal third quarter 2025 financial results, revealing total revenues of $60.6 million, a decrease from $84.0 million in the same quarter of the previous year. This decline was primarily attributed to a $15.7 million year-over-year negative difference related to the accrual in 3Q24 of Syngenta's initial downpayment. The company recorded a net loss of $1.6 million, while its Adjusted EBITDA was $9.0 million. Operating profit for the quarter stood at $0.9 million. Significant improvements were noted in net cash flow from operating activities, which reached $23.3 million, a substantial increase of $40.7 million compared to 3Q24. These improvements were largely driven by efficiencies in working capital management, including enhanced inventory management and accounts receivables performance. Segment-wise, Crop Protection revenues fell by 19% to $38.0 million, while Seed and Integrated Products saw a 26% increase, reaching $10.9 million. Crop Nutrition revenues experienced a significant decline of 59%, totaling $11.8 million. Gross profit was reported at $23.8 million, down from $42.6 million in the previous year, leading to a reduced gross margin of 39%. In terms of business developments, Bioceres achieved a significant milestone with the EPA registration of its Rinotec™ insecticide and nematicide platform, marking a key advancement in its biological solutions portfolio for integrated pest management.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。